[go: up one dir, main page]

FI964893L - Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vapauttamistekijän (CRF) antagonisteina - Google Patents

Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vapauttamistekijän (CRF) antagonisteina Download PDF

Info

Publication number
FI964893L
FI964893L FI964893A FI964893A FI964893L FI 964893 L FI964893 L FI 964893L FI 964893 A FI964893 A FI 964893A FI 964893 A FI964893 A FI 964893A FI 964893 L FI964893 L FI 964893L
Authority
FI
Finland
Prior art keywords
corticotropin
crf
antagonists
releasing factor
substituted pyrazoles
Prior art date
Application number
FI964893A
Other languages
English (en)
Swedish (sv)
Other versions
FI964893A0 (fi
FI964893A7 (fi
Inventor
Gene M Bright
Jr Willard M Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI964893A0 publication Critical patent/FI964893A0/fi
Publication of FI964893L publication Critical patent/FI964893L/fi
Publication of FI964893A7 publication Critical patent/FI964893A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI964893A 1994-06-06 1995-05-04 Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina FI964893A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25482094A 1994-06-06 1994-06-06
PCT/IB1995/000318 WO1995033727A1 (en) 1994-06-06 1995-05-04 Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity

Publications (3)

Publication Number Publication Date
FI964893A0 FI964893A0 (fi) 1996-12-05
FI964893L true FI964893L (fi) 1996-12-05
FI964893A7 FI964893A7 (fi) 1996-12-05

Family

ID=22965708

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964893A FI964893A7 (fi) 1994-06-06 1995-05-04 Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina

Country Status (13)

Country Link
US (1) US5968944A (fi)
EP (1) EP0764153A1 (fi)
JP (1) JP3291299B2 (fi)
KR (1) KR100263429B1 (fi)
CN (1) CN1149870A (fi)
AU (1) AU2265495A (fi)
CA (1) CA2192208C (fi)
FI (1) FI964893A7 (fi)
IL (1) IL113911A0 (fi)
NO (1) NO965209D0 (fi)
NZ (1) NZ284143A (fi)
WO (1) WO1995033727A1 (fi)
ZA (1) ZA954598B (fi)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
JP3806144B2 (ja) * 1993-12-22 2006-08-09 セルテック セラピューティックス リミテッド 三置換フェニル誘導体、その調製方法とホスホジエステラーゼ（ｉｖ型）阻害剤としてのその使用
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
AU725254B2 (en) * 1996-03-26 2000-10-12 Du Pont Pharmaceuticals Company Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP1380298A3 (en) * 1996-05-23 2004-04-07 Bristol-Myers Squibb Pharma Company Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
WO1998042699A1 (en) * 1997-03-26 1998-10-01 Taisho Pharmaceutical Co., Ltd. 4-tetrahydropyridylpyrimidine derivatives
IL133800A0 (en) 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
JP2001514260A (ja) 1997-09-02 2001-09-11 デュポン ファーマシューティカルズ カンパニー Ｃｎｓおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
US6518266B1 (en) 1999-07-22 2003-02-11 3-Dimensional Pharmaceuticals 1- Aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
WO2001025241A2 (en) 1999-10-06 2001-04-12 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
EP1244666A1 (en) 1999-12-17 2002-10-02 Bristol-Myers Squibb Pharma Company Imidazopyrimidinyl and imidazopyridinyl derivatives
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001058489A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Preventives/remedies for postoperative stress
GB0016453D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
DE50213202D1 (de) 2001-05-29 2009-02-26 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
US8795565B2 (en) 2006-02-21 2014-08-05 Celgard Llc Biaxially oriented microporous membrane
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2624967A1 (de) * 1975-06-13 1976-12-23 Sandoz Ag Neue organische verbindungen, ihre herstellung und verwendung
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
ATE187451T1 (de) * 1992-12-17 1999-12-15 Pfizer Substituierte pyrazole als crf antagonisten
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists

Also Published As

Publication number Publication date
NO965209L (no) 1996-12-05
KR970703332A (ko) 1997-07-03
IL113911A0 (en) 1995-08-31
NZ284143A (en) 1999-01-28
WO1995033727A1 (en) 1995-12-14
CA2192208C (en) 2002-09-10
FI964893A0 (fi) 1996-12-05
NO965209D0 (no) 1996-12-05
CA2192208A1 (en) 1995-12-14
ZA954598B (en) 1996-12-05
JPH09506632A (ja) 1997-06-30
CN1149870A (zh) 1997-05-14
US5968944A (en) 1999-10-19
FI964893A7 (fi) 1996-12-05
EP0764153A1 (en) 1997-03-26
KR100263429B1 (ko) 2000-08-01
JP3291299B2 (ja) 2002-06-10
AU2265495A (en) 1996-01-04

Similar Documents

Publication Publication Date Title
FI964893L (fi) Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vapauttamistekijän (CRF) antagonisteina
NO973167L (no) Bestemte 1,4,5-trisubstituerte imidazol-forbindelser anvendelige som cytokin
FI964894L (fi) Kortikotropiinia vapauttavan tekijän antagonisteja
EE9900211A (et) Asendatud pürasooliderivaadid
ZA945193B (en) Novel 1-substituted imidazole compounds as cytokine inhibitors.
HUT77641A (hu) Mozgatható, széthajtható épület
DE69404144D1 (de) Bauschiger, stabiler vliesstoff
NO995695D0 (no) Substituerte pyrazoler som p38-kinase-inhibitorer
NO983181L (no) Nye substituerte imidazolforbindelser
DE59511103D1 (de) 1-h-3-aryl-pyrrolidin-2,4-dion-derivate als schädlingsbekämpfungsmittel
FI971234L (fi) Imidatsolijohdannainen
DE69535599D1 (de) Kommunikationsendgerät
FI935672L (fi) Substituoituja pyratsoleja
PT946515E (pt) Pirazoles parasiticidas
DE69613128D1 (de) Wegsuche in kommunikationsnetzwerken
TR199501561A2 (tr) Imidazol türevleri.
FI972684A7 (fi) Piperidiinietikkahappojohdannaisia, joita voidaan käyttää fibrinogeeni antagonisteina
FI932516A7 (fi) Styrkonsol, i synnerhet foer motorfordon
PT918756E (pt) Pirazoles parasiticidas
NO961333D0 (no) Nye pyrazolderivater som angiotensin-II-antagonister
FI942792L (fi) Lipoksigenaasia inhiboivia imidatsoliyhdisteitä
FR2745469B1 (fr) Pyrazoles fongicides
ID24193A (id) Komponen bangunan seperti kayu gelondongan penunjang sendiri
FI972201A7 (fi) Viestiliikenneverkko
DE59704842D1 (de) Reihenklemme, insbesondere Initiator-Aktor-Klemme

Legal Events

Date Code Title Description
MA Patent expired